Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Banyu Launches Merck’s Isentress HIV Drug In Japan

This article was originally published in PharmAsia News

Executive Summary

Banyu Pharmaceutical launched in Japan the HIV treatment Isentress (raltegravir), the only drug of its kind for blocking the virus that causes AIDS. The drug works by inserting viral DNA into human DNA to inhibit the integrase enzyme. Banyu is a wholly owned subsidiary of U.S. drug maker Merck. The drug also can help HIV-infected people who have developed a resistance to other drugs. (Click here for more - a subscription may be required



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts